Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016831 | 1.00 | EGFR (0.34) | EGFRCALM1FFAR4MAPK1SIRT2 | |
| SCHEMBL17021076 | 0.92 | EGFR (0.34) | EGFRCALM1FFAR4MAPK1SIRT2 | |
| SCHEMBL17016826 | 0.92 | EGFR (0.34) | EGFRCALM1FFAR4MAPK1SIRT2 | |
| SCHEMBL17020998 | 0.86 | TACR2 (0.39) | EGFRFFAR4MAPK1PKMKMT2A | |
| SCHEMBL17016856 | 0.86 | TACR2 (0.39) | EGFRFFAR4MAPK1PKMKMT2A | |
| SCHEMBL17021068 | 0.83 | FFAR4 (0.37) | EGFRCALM1FFAR4PKMKMT2A | |
| SCHEMBL17016793 | 0.83 | FFAR4 (0.37) | EGFRCALM1FFAR4PKMKMT2A | |
| SCHEMBL17016833 | 0.82 | CALM1 (0.33) | EGFRCALM1FFAR4PPARGPPARD | |
| SCHEMBL17021046 | 0.82 | CALM1 (0.33) | EGFRCALM1FFAR4PPARGPPARD | |
| SCHEMBL20346149 | 0.81 | FFAR4 (0.43) | CALM1FFAR4MAPK1SIRT2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, LEO1 | EGFR 735/4885CALM1 2438/4885FFAR4 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.